Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Cellectis SA ( (CLLS) ).
Cellectis announced the acceptance of two abstracts for presentation at the ASH 2025 annual meeting, highlighting significant advancements in their clinical trials. The first abstract presents promising preliminary data for eti-cel (UCART20x22) in treating relapsed/refractory non-Hodgkin lymphoma, showing an 86% overall response rate and a 57% complete response rate. The second abstract discusses the correlation between alemtuzumab exposure and response in patients treated with lasme-cel (UCART22) for acute lymphoblastic leukemia, indicating improved responses without increased toxicities. These developments underscore Cellectis’ potential to enhance treatment outcomes for challenging cancer cases.
The most recent analyst rating on (CLLS) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Cellectis SA stock, see the CLLS Stock Forecast page.
Spark’s Take on CLLS Stock
According to Spark, TipRanks’ AI Analyst, CLLS is a Neutral.
Cellectis SA’s overall stock score is driven by its strong technical momentum and positive developments from the earnings call, including strategic partnerships and clinical trial progress. However, financial performance challenges and valuation concerns due to ongoing losses and lack of dividend yield weigh down the score.
To see Spark’s full report on CLLS stock, click here.
More about Cellectis SA
Cellectis is a clinical-stage biotechnology company that utilizes a pioneering gene-editing platform to develop life-saving cell and gene therapies. The company focuses on allogeneic CAR T immunotherapies in oncology, offering off-the-shelf, ready-to-use gene-edited CAR T-cells for cancer treatment. Cellectis controls the entire cell and gene therapy value chain with in-house manufacturing capabilities and is listed on the Nasdaq Global Market and Euronext Growth.
Average Trading Volume: 139,538
Technical Sentiment Signal: Buy
Current Market Cap: $256.4M
For an in-depth examination of CLLS stock, go to TipRanks’ Overview page.